CROs Gaining a Competitive Edge

VITALII VODOLAZSKYI - STOCK.ADOBE.COM

Advanced therapeutic medicinal products (ATMPs) are experiencing a boom, with the global pipeline continuing to experience growth and more than 3700 ATMPs currently under development, according to data from the American Society of Gene and Cell Therapy. However, progressing such complex therapies that target niche disease areas through to commercialization produces a unique set of challenges.

Critically, the technical expertise required for the clinical research of ATMPs is something that can be lacking for developers in-house, driving demand for contract research organizations (CRO). In fact, the cell and gene therapy CRO market is forecast to experience continued and consistent growth until 2035.

In this feature, Rhonda Henry, president of Emmes BioPharma; Ching Tian, chief innovation officer, Emmes; and Raja Sharif, CEO Hataali, detail the challenges facing biopharma companies developing ATMPs and the role that CROs play in gaining a market advantage.

Read this article in BioPharm International’s May 2023 Partnerships for Outsourcing eBook.

About the author

Felicity Thomas is European/senior editor for BioPharm International

Article details

BioPharm International
eBook: Partnerships for Outsourcing
May 2023
Pages: 8–11

Citation

When referring to this article, please cite it as Thomas, F. CROs Gaining a Competitive Edge. BioPharm International’s Partnerships for Outsourcing eBook (May 2023).